ACG, an India-based provider of solid-dosage solutions, announced on Monday a USD200m phased investment to establish its first empty-capsule manufacturing operations in the United States.

The initial USD100m will fund a state-of-the-art hard-shell capsule facility in Atlanta, Georgia, with a second phase of USD100m planned to expand capacity and capabilities in the region. The investment is expected to create more than 200 jobs, with operations targeted to begin in early 2027.

ACG said that it will establish dedicated facilities to manufacture gelatine and vegetarian (HPMC) hard-shell capsules, designed and operated to the highest global standards of quality, safety, and regulatory compliance. This complements the company's US ecosystem spanning capsules, barrier packaging materials, processing and encapsulation machinery, visual inspection, and traceability solutions -- supported by nationwide sales and service.

ACG has operated in the United States for more than 25 years, with North American headquarters in Piscataway, N.J., manufacturing liquid fill capsules in Chadds Ford, Pa., warehouses across the United States, and sales and service teams nationwide.